Systematic Review

HIV-free survival at 12–24 months in breastfed infants of HIV-infected women on antiretroviral treatment

Lana Clara Chikhungu1, Stephanie Bispo2, Nigel Rollins3, Nandi Siegfried4 and Marie-Louise Newell5

1 School of Languages and Area Studies, University of Portsmouth, Portsmouth, UK
2 Department of Social Statistics and Demography, University of Southampton, Southampton, UK
3 Department of Maternal, New-born, Child and Adolescent Health, World Health Organization, Geneva, Switzerland
4 Independent Clinical Epidemiologist
5 Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK

Abstract

OBJECTIVE To provide estimates of HIV-free survival at 12–24 months in breastfed children by maternal ART (6 months or lifelong) to inform WHO HIV and Infant Feeding guidelines.

METHODS Eighteen studies published 2005–2015 were included in a systematic literature review (1295 papers identified, 156 abstracts screened, 55 full texts); papers were analysed by narrative synthesis and meta-analysis of HIV-free survival by maternal ART regimen in a random effects model. We also grouped studies by feeding modality. Study quality was assessed using a modified Newcastle–Ottawa Scale (NOS) and GRADE.

RESULTS The pooled estimates for 12-month HIV-free survival were 89.8% (95% confidence interval, CI: 86.5%, 93.2%) for infants of mothers on ART for 6 months post-natally (six studies) and 91.4% (95% CI 87.5%, 95.4%) for infants of mothers on lifelong ART (three studies). Eighteen-month HIV-free survival estimates were 89.0% (95% CI 83.9%, 94.2%) with 6 months ART (five studies) and 96.1% (95% CI 92.8%, 99.0%) with lifelong ART (three studies). Twenty-four-month HIV-free survival for infants whose mothers were on ART to 6 months post-natally (two studies) was 89.2% (95% CI 79.9%, 98.5%). Heterogeneity was considerable throughout. In four studies, HIV-free survival in breastfed infants ranged from 87% (95% CI 78%, 92%) to 96% (95% CI 91%, 98%) and in formula-fed infants from 67% (95% CI 35.5%, 87.9%) to 97.6% (95% CI 93.0%, 98.2%).

CONCLUSION Our results highlight the importance of breastfeeding for infant survival and of ART in reducing the risk of mother-to-child HIV transmission and support the WHO recommendation to initiate ART for life immediately after HIV diagnosis.

KEYWORDS HIV-free survival, antiretroviral treatment, women, systematic review

Introduction

The 2010 WHO infant feeding guidelines in the context of HIV infection recommended exclusive breastfeeding (EBF) for 6 months followed by complementary feeding and continued breastfeeding (CBF) for up to 1 year, under the cover of antiretroviral treatment (ART) to either the mother or the infant [1]. However, these recommendations were based on limited evidence in terms of final HIV-free survival and also toxicity of ART to infants where the infant received prophylaxis to prevent mother-to-child transmission (PMTCT). Since then, further evidence has become available from studies and programmes where PMTCT post-natally was achieved through maternal ART or infant ARV prophylaxis, and a summary of these data could provide information for recommendations on duration of breastfeeding.

In late 2015, WHO revised HIV ART guidelines to include treatment for all immediately upon diagnosis of HIV infection [2]. This systematic review was commissioned by WHO and contributed to the development of the 2015 WHO HIV Infant Feeding guidelines. We present the results from a systematic review and the associated GRADE evidence summary tables of HIV-free survival at 12, 18 and 24 months in infants born to...
women on ART for life or for 6 months post-partum and by infant feeding modality.

Methods

Our systematic review considered both experimental and observational studies and included HIV-positive mothers receiving ART and their breastfed children. Infants may also have received prophylactic ART as per WHO 2010 guidelines. Exposure was defined as HIV ART (and duration) and breastfeeding (and duration), and outcome measures were HIV-free survival and overall and post-partum HIV transmission between birth and 24 months of age.

SB, LB and MLN searched English literature from multiple electronic databases including PubMed, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science and CINAHL for articles published between 2005 and 2015. The search words in PubMed are shown in a footnote to Figure 1. The search terms were adapted for other databases.

Reference lists from relevant studies, grey literature and online abstracts from the International IAS AIDS Conference in Melbourne 2014 and the 2013–2015 Conferences on Retroviruses and Opportunistic Infections were also searched. Reference lists of articles identified from the search of databases and conference abstracts were scrutinised, and in cases where relevant information was not available in the publication, authors were contacted for specific additional information regarding infant feeding modality.

The quality of studies included in the analysis was assessed using a modified Newcastle–Ottawa Scale (NOS) [3, 4] (Table S1). Although some of the included studies were nested within randomised controlled trials, randomisation was not based on the intervention of interest (breastfeeding) and these studies were considered cohorts. Each study could score a maximum of six stars on selection and four on outcome; factors considered included the representativeness of the study population, ascertainment of exposure to ART and breastfeeding, initiation on basis of ART eligibility, maternal adherence to ART and duration of breastfeeding. Ascertainment of outcome (HIV-free survival) included timing of assessment and whether the outcome was stratified by feeding, length of follow-up and loss to follow-up.

The information obtained from the NOS was used to comment on the quality of the included studies in GRADE with respect to study limitations/risk of bias [5]. We also considered consistency of results, directness, precision and publication bias.

Synthesis of evidence

We undertook a narrative synthesis and obtained pooled estimates of HIV-free survival with a heterogeneity score based on a random effects meta-analysis in STATA 13 (Stata Corp, 2013). We also summarised the information in graphs depicting HIV-free survival rates by duration of maternal ART where possible and additionally presented HIV transmission rates for studies that provided transmission rates at 6 months and at the end of follow-up. If no confidence interval for HIV-free survival estimated was provided, it was calculated based on the number of events and those at risk using the formula described by Eayres [6].

Results

The search process identified 1295 citations, of which 1139 were excluded on the basis of being a duplicate, review, qualitative study or not evaluating transmission, mortality or HIV-free survival (Figure 1). Abstracts of the remaining 156 studies were evaluated by SB and LC, and 54 texts were selected for full screening. SB, LC and MLN undertook the full-text screening. Six additional articles from the references were identified through full-text screening, bringing the total to 60 (Figure 1). Eighteen studies were included in the analysis. Details of excluded studies with reason are provided in Table S2. Eight additional papers from selected studies provided additional information for the assessment of quality of studies and data collection [7–14].

We present the evidence using a narrative synthesis, in addition to providing a pooled estimate with a heterogeneity score based on a random effects meta-analysis, as recommended for use in the analysis of studies of different design [15]. Of the 18 selected studies, one was performed in India and the remaining 17 were from African countries. Five studies were conducted in rural areas [16–20] and the remainder in urban areas. All 18 were cohort studies, of which seven were nested within randomised clinical trials (see Table S3 for full study details). Most studies were a follow-up of mothers receiving ART for prevention of mother-to-child transmission (PMTCT) [16, 18, 19, 21–25], with mothers advised to exclusively breastfeed for 6 months with rapid weaning thereafter, in line with the prevailing WHO recommendations. Seven studies offered lifelong ART irrespective of CD4 count and supported breastfeeding for 12 months [16, 21, 22, 25–28]. Thomas et al. [29] presented findings from a clinical trial evaluating two combination ART regimen, which was included as a cohort of all women on ART post-natally. Thakwalakwa et al. [16] randomised
mothers/infants post-partum to two types of complementary foods after weaning; all mothers received ART lifelong including throughout the breastfeeding period.

Tonwe-Gold et al. [25] presented findings of a cohort of women who received ART for life if they were ART-eligible as per prevailing WHO guidelines or who received short-course ART for PMTCT only; data are included accordingly.

The seven cohorts nested within clinical trials evaluated the use of ART during pregnancy and post-natally in reducing mother-to-child transmission (MTCT) of HIV and infant deaths [8, 16, 28–32]. Cournil et al. [8] in the

---

**Figure 1** Flowchart of screening process. Search Terms in PubMed (((Maternal[Title/Abstract] OR mother*[Title/Abstract]) AND (Antiretroviral therapy[Title/Abstract] OR Antiretroviral*[Title/Abstract] OR ART[Title/Abstract] OR ARV[Title/Abstract] OR HAART[Title/Abstract]) AND (HIV free survival[Title/Abstract] OR HIV[Title/Abstract] OR Transmis*[Title/Abstract] OR Death[Title/Abstract] OR Mortality[Title/Abstract]) AND (Breastfeeding[Title/Abstract] OR Postnatal[Title/Abstract] OR Breast*[Title/Abstract])) AND (“2005”[Publication Date] : “2015”[Publication Date])).
Kesho Bora study compared ART through 6 months of breastfeeding with short duration of peripartum ART and presented HIV-free survival in children who were never breastfed and those who were breastfed for more than 3 months. Jamieson et al. [32] and Coovadia et al. [30] compared rates and risk by prolonged infant nevirapine prophylaxis, with mothers on different types of ART, but provided separate estimates on HIV-free survival for the group of mothers on ART for at least 6 months.

Quality of studies

Table S4 presents findings of the assessment of the quality of the studies based on the modified Newcastle–Ottawa Scale. The study by Ngoma et al. [27] had the highest quality in terms of selection (six stars), followed by Sagay et al. et al. [26], Cohan et al. [28], Jamieson et al. [32], Thomas et al. [29] and Peltier et al. [20], all with 4 stars. The studies by Alvarez-Uria et al. [17] and Tonwe-Gold et al. [25] scored highest on quality of outcome assessment (4 stars).

Most studies did not provide details on type of feeding and assumed (but did not formally document) that most mothers exclusively breastfed up to 5 or 6 months as recommended. Estimates of HIV-free survival by type of feeding could only be obtained from four studies [8, 17, 19, 20]. Tonwe-Gold [25] presented information on HIV transmission by feeding type and Cournil et al. [8] presented rates in children who were either formula-fed from birth, breastfed for less than 3 months or for 3 months or longer. Three studies compared transmission or death between breastfed and formula-fed infants [17, 19, 20].

Eleven studies provided HIV-free survival or rates of transmission and mortality from birth [18, 19, 23–29, 31, 32]. Other studies excluded deaths and HIV transmission in the first days or weeks of life and provided only postnatal rates.

HIV-free survival

At age 12 months. Estimates of 12-month HIV-free survival, with confidence intervals, for breastfed infants by duration of maternal ART were obtained from 10 studies (Figure 2). In six studies (Group 1 in Figure 2), HIV-free survival was reported for infants whose mothers were on ART up to 6 months post-natally only, with 12-month estimates ranging from 85% (95% CI 74.6–91.7%) [18] to 96% (95% CI 91–98%) [17]. The pooled estimated 12-month HIV-free survival was 89.8% (95% CI 86.4–93.2%), with considerable heterogeneity ($I^2 = 83.1$).

In three studies, 12-month HIV-free survival was estimated amongst infants whose mothers were on lifelong ART (Group 2 in Figure 2) with estimated HIV-free survival ranging from 88.8% (95% CI 82.6–95%) [25] to 95% (95% CI 92–97%) [28]. The pooled estimate of 12-month HIV-free survival was 91.8% (95% CI 87.7–95.9%); heterogeneity was considerable ($I^2 = 71.5$). The study by Giuliano [22] (Group 3 in Figure 2), with an estimate of 86.6% (95% CI 82.4–90.7%) included some mothers on ART up to 6 months post-natally only and others on lifelong ART, but separate estimates were not provided.

At age 18 months. Eight studies provided estimates for 18-month HIV-free survival (Figure 3), by duration of maternal ART. In the five studies reporting HIV-free survival at this age for infants of women who were on ART up to 6 months post-natally only (Group 1 in Figure 3), HIV-free survival ranged from 81.6% (95% CI 73.4–87.7%) [19] to 95.2% (95% CI 93.2–97.3%) [10]. The pooled estimate of 18-month HIV-free survival for this group was 89.0% (95% CI 83.9–94.2%), with considerable heterogeneity ($I^2 = 91.7$).

In studies where women were on lifelong ART (Group 2 in Figure 3), 18-month HIV-free survival estimates ranged from 87.2% (95% CI 79.2–92.5%) [27] to 97.6% (95% CI 96.7–98.6%) [26]. The pooled estimated of 18-month HIV-free survival for this group was 96.1% (95% CI 93.0–99.2%), again with considerable heterogeneity ($I^2 = 78.5$).

At age 24 months. Twenty-four-month HIV-free survival estimates from three studies are shown in Figure 4. The estimates in the two studies that reported HIV-free survival amongst children whose mothers were on ART up to 6 months post-natally only (Group 1 in Figure 4) were 84.3% (95% CI 80.6–87.3%) [29] and 93.8% (95% CI 92.9–96.5%) [31]. The pooled estimate for HIV-free survival at 24 months was 89.2% (95% CI 79.9–98.5%); heterogeneity was considerable ($I^2 = 95.8$).

In the study by Giuliano et al. [22], (Group 2 in Figure 4) estimated HIV-free survival at 24 months was 85.8% (95% CI 81.4–90.1%), based on a mixed group of infants with respect to mother’s ART, some were on ART up to 6 months post-natally only, while others were on ART for life.

At 12, 18 and 24 months. Three studies provided estimates of HIV-free survival at 12, 18 and 24 months allowing a comparison of HIV-free survival between 12 and 24 months [22, 23, 29]. In all three, HIV-free survival at 18 months and/or 24 months was not statistically
significantly different from the estimate at 12 months. HIV-free survival estimates were 86.6% (95% CI 82.4%, 90.7%) and 85.8% (95% CI 81.4, 90.1%) at 12 and 24 months, respectively, in Giuliano et al. [22], 86.5% (95% CI 83.1%, 89.3%), 84.7% (95% CI 80.6%, 87.7%) and 84.3% (95% CI 80.6%, 87.3%) at 12, 18 and 24 months, respectively, in Thomas et al. [29], and in Kilewo et al. [23], the estimates were 87.2% (95% CI 84%, 90.4%) at 12 months and 86.4% (95% CI 83.1%, 89.7%) at 18 months.

HIV-free survival by infant feeding modality. In the Kesho Bora study [8, 9], estimated 18-month HIV-free survival was statistically significantly higher amongst formula-fed (97.6%; 95% CI 93%, 98%) than infants breastfed for less than 3 months (87%; 95% CI 78%, 92%) (Figure 5). The difference between formula-fed infants (97.6%; 95% CI 93%, 98%) and those breastfed for more than 3 months (95%; 95% CI 91%, 97%) was not statistically significant. In the studies by Alvarez-Uriae [17], reporting estimates at 18 months, Homsy et al. [19] at 12 months and Pellett et al. [20] at 9 months differences in HIV-free survival between formula-fed and breastfed infants were not statistically significant (Figure 5).

HIV Transmission. Eight studies provided estimates of death and transmission overall and after 6 months of age, when the infant would have been weaned and mothers were no longer receiving ART. In Ngoma et al. [27], there were three peripartum infections, none between 6 weeks and 6 months, and 6 after 6 months. In the studies of both Giuliano et al. [22] and Kilewo et al. [23], there were eight infections overall, four before weaning at 6 months and four after weaning. In the study by Giuliano et al., two of the four mothers who transmitted HIV after weaning were still receiving ART. In the other five studies, there were fewer infections after 6 months of age than before [8, 24, 26, 29, 32], but numbers were again very limited.

Mortality. The pattern of infant deaths before and after weaning varied across studies. Jamieson et al. [32] reported the same number of deaths before and after weaning (9 of 18 deaths before weaning); Tonwe-Gold [25] reported one death after and nine deaths before weaning and Ngoma et al. [27] reported eight of 20 deaths after weaning. Thomas et al. [29], Shapiro et al. [31], Kilewo et al. [23.] and Marazzi et al. [24.] reported higher numbers of deaths after (31 of 49, 22 of 37, 21 of 31 and 7 of 11, respectively) than before weaning. In Shapiro [31], the death rate within 3 months of weaning was significantly higher than during breastfeeding (RR 3.7; 95% CI: 1.3–12.0; P = 0.007), and the same was shown comparing those who were weaned before 3 months of age and those aged 3 months or more at weaning (RR = 7.5; 95% CI: 3.2–18.4; P < 0.001). Cournil et al. [8] did not report any deaths after weaning.

### Table 1: Twelve-month HIV-free survival of breastfed infants of women on ART

| Study (Information) | Rate (95% CI) | % Weight |
|---------------------|--------------|----------|
| 1                   |              |          |
| Jamieson et al. 2012 (EBF: 89%; N = 849) | 88.0 (85.0, 90.0) | 19.3 |
| Alvarez-Uria et al. 2012 (N = 151) | 96.0 (91.0, 98.0) | 17.4 |
| Thomas et al. 2011 (EBF: 89%; N = 502) | 86.5 (83.1, 89.3) | 18.1 |
| Thistle et al. 2011 (N = 82) | 85.0 (74.6, 91.7) | 09.1 |
| Marazzi et al. 2009 (EBF: 100%; N = 341) | 94.0 (91.0, 97.0) | 18.3 |
| Kilewo et al. 2009 (EBF: 80%; N = 441) | 87.2 (84.0, 90.4) | 17.9 |
| Overall (I-squared = 83.1%, P = 0.000) | 89.8 (86.4, 93.2) | 100.0 |

| 2                   |              |          |
| Cohan et al. 2015 (EBF: 59.8%; N = 389) | 95.0 (92.0, 97.0) | 41.1 |
| Thakwalakwa et al. 2014 (EBF: 87%; N = 248) | 90.0 (87.0, 94.0) | 35.9 |
| Tonwe-Gold et al. 2007 (EBF: 62.6%; N = 261) | 88.8 (82.6, 95.0) | 23.0 |
| Overall (I-squared = 71.5%, P = 0.030) | 91.8 (87.7, 95.9) | 100.0 |

| 3                   |              |          |
| Giuliano et al. 2013 (EBF: 73%; N = 300) | 86.6 (82.4, 90.7) | 100.0 |
| Overall (I-squared = 0%) | 86.6 (82.4, 90.7) | 100.0 |
6 months, but the risk of dying by 6 months of age in children who stopped breastfeeding before 3 months of age was higher than in those who stopped after more than 3 months (HR 3.94; 95% CI: 1.27–12.27).

**GRADE profile**

An evaluation of the overall quality of the combined studies for each outcome is provided in Table S5 using the GRADE approach [5]. Study limitations were based on the assessment from the Newcastle–Ottawa Scale and combined with an evaluation of inconsistency, indirectness, imprecision and publication bias. All studies were observational and initially scored as low quality; they were further downgraded for indirectness because their research areas were not directly in line with the research question. Where a pooled analysis was undertaken and a pooled estimate provided, studies were further downgraded for inconsistency when heterogeneity could not be explained. In all groups of studies, there was at least one study with a risk of bias pertaining to lack of detailed information on feeding leading to further downgrading. In one study, the criteria for assessing HIV-free survival were not clear [21] and this contributed to the downgrading of the quality of the studies grouped together with this study. One study [22] was not downgraded for risk
of bias and inconsistency, as it was the single study contributing data in that group.

**Discussion**

This systematic review confirms substantially reduced rates of overall and post-natal HIV transmission and mortality up to 24 months of age when pregnant and breastfeeding women receive ART. The difference in HIV-free survival between infants of mothers receiving ART for PMTCT only or for life diverged beyond 6 months post-delivery and became particularly evident at 18 months. At this time-point, the estimated HIV-free survival was about 89% when mothers ceased ART at 6 months, and 96% when mothers continued ART for life. The risk of transmission through breastfeeding continued beyond the recommended 6 months and after cessation of maternal ART [1].

Our results thus confirm the importance of breastfeeding for infant survival and the effectiveness of ART in reducing the risk of mother-to-child HIV transmission. In most studies (5 of 8), there were more infant deaths after weaning than before, but in only one of eight studies was the number of HIV transmissions after 6 months higher than before, which together would suggest that HIV-free survival in the first year of life is substantially affected by increased mortality following early cessation of breastfeeding rather than by increased infections that may occur in infants of women who had stopped taking ART [8, 22–25, 27, 29, 31, 32].

Our review, although systematic in nature, had limitations. There was considerable statistical heterogeneity in all pooled estimates, and the overall assessment of quality of the evidence was very low. The low quality of evidence was mainly attributed to the fact that all studies included in the analysis were observational and the evidence was further downgraded due to indirectness, and lack of data on feeding history and adherence to ART. The absolute estimates of HIV-free survival should thus be interpreted with caution and consider both the mean value and the confidence interval limits. Further, we were unable to formally allow for factors known to be associated with transmission and/or child survival, and heterogeneity between studies could be partially due to differences in other factors associated with child mortality. There was limited information on children born to women on lifelong ART where ART was initiated before advanced HIV progression, and most of the women on lifelong ART in the studies that reported such information would have been eligible as per the national and WHO guidelines at the time of the study [16, 21, 25–28].

Increased HIV-free survival in the studied populations was linked to early initiation of maternal ART in pregnancy, continued post-partum and breastfeeding. Increased infant/child mortality after 6 months of life may be attributed to early cessation of breastfeeding and
could possibly contribute to reduced HIV-free survival in non-breastfed HIV-exposed infants. Recent findings from a randomised trial, evaluating the use of two different infant antiviral drugs in the prevention of post-natal HIV acquisition, showed HIV-free survival similar to what we present here with maternal ART [33]; infant ARV may therefore be an alternative intervention to achieve the prevention of mother-to-child transmission in cases where maternal ART is not possible or not being adhered to. Our findings suggest prolonged breastfeeding for women on ART for life is beneficial in terms of HIV-free survival at least up to 2 years of age. With expanding eligibility criteria, and WHO now recommending initiation of ART for life immediately after HIV diagnosis, most women will be on ART for life from before or early pregnancy.

Acknowledgements
This systematic review was commissioned and funded by the World Health Organization. The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the views, decisions or policies of the World Health Organisation.

References
1. WHO. Guidelines on HIV and Infant Feeding 2010: Principles and recommendations for infant feeding in the context of HIV and a summary of evidence. Geneva, Switzerland 2010. (Available from: http://apps.who.int/iris/bitstream/10665/44345/1/9789241595353_eng.pdf) [10 July 2015].
2. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection: What’s new. Geneva, Switzerland 2015. (Available from: http://www.who.int/hiv/pub/guidelines/2013/en) [10 July 2015].
3. Wells GA, Shea B, O’Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta analysis 2000. (Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) [5 Sept 2015].
4. MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ 2014; 92: 126–138.
5. Guyatt G, Andrew D, Gunn E, Kunz R, Falck-Ytter Y, Schunemann HJ. GRADE: what is “quality of evidence” and why is it important to clinicians? BMJ 2008: 336: 995–998.
6. Eayres D. Technical Briefing 3. Commonly used public health statistics and their confidence intervals. National Centre for Health Outcomes Development 2008. (Available from: www.apho.org.uk/resource/view.aspx?RID=48457) [15 May 2015].
7. The-Kesho-Bora-Study-Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011; 11: 171–180.
8. Cournil A, Van de Perre P, Cames C et al. Early infant feeding patterns and HIV-free survival: findings from the Kesho-Bora trial (Burkina Faso, Kenya, South Africa). Pediatr Infect Dis J. 2015; 34: 168–174.
9. The-Kesho-Bora-Study-Group. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr. 2010: 54: 533–541.
10. Fowler MG, Coovadia H, Herron CM et al. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr 2014: 65: 366–374.
11. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS. 2007: 21 (Suppl. 4): S65–S71.
12. Shapiro RL, Smeaton L, Lockman S et al. Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana. J Infect Dis 2009: 199: 414–418.
13. Shapiro RL, Hughes MD, Ogwu A et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010: 362: 2282–2294.
14. Okanda JO, Borkowf CB, Girde S, Thomas TK, Lecher SL. Exclusive breastfeeding among women taking HAART for PMTCT of HIV-1 in the Kisumu Breastfeeding Study. BMC Pediatr 2014: 14: 280.
15. Borestein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Wiley: West Sussex, UK, 2009.
16. Thakwalakwa C, Phiri A, Rollins N, Heikens GT, Barnell EK, Manary M. Growth and HIV-free survival of HIV-exposed infants in Malawi: a randomized trial of two complementary feeding interventions in the context of maternal antiretroviral therapy. J Acquir Immune Defic Syndr 2014: 66: 181–187.
17. Alvarez-Uria G, Midde M, Pakam R, Bachu L, Naik PK. Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India. ISRN Pediatr 2012: 2012: 763591.
18. Thistle P, Bolotin S, Lam E et al. Highly active anti-retroviral therapy in the prevention of mother-to-child transmission of HIV in rural Zimbabwe during the socio-economic crisis. Med Confl Surviv 2011: 27: 165–176.
19. Homsey J, Moore D, Barasa A et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral
therapy in rural Uganda. J Acquir Immune Defic Syndr 2010: 53: 28–35.

20. Peltier CA, Ndayisaba GF, Lepage P et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009: 23: 2415–2423.

21. Okafor I, Ugwu E, Obi S, Odugu B. Virtual Elimination of Mother-to-Child Transmission of Human Immunodeficiency Virus in Mothers on Highly Active Antiretroviral Therapy in Enugu, South-Eastern Nigeria. Ann Med Health Sci Res 2014: 4: 615–618.

22. Giuliano M, Andreotti M, Liotta G et al. Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. PLoS ONE 2013: 8: e68950.

23. Kilewo C, Karlsson K, Ngarina M et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009: 52: 406–416.

24. Marazzi MC, Nielsen-Saines K, Buonomo E et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breastfeeding. Pediatr Infect Dis J 2009: 28: 483–487.

25. Tonwe-Gold B, Ekouevi DK, Viho I et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007: 4: e257.

26. Sagay AS, Ebohny AO, Meloni ST et al. Mother-to-Child Transmission Outcomes of HIV-Exposed Infants Followed Up in Jos North-Central Nigeria. Curr HIV Res 2015: 13: 193–200.

27. Ngoma MS, Misir A, Mutale W et al. Efficacy of WHO recommendation for continued breastfeeding and maternal cART for prevention of perinatal and postnatal HIV transmission in Zambia. J Int AIDS Soc 2015: 18: 19352.

28. Cohan D, Natureeza P, Koss CA et al. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS 2015: 29: 183–191.

29. Thomas TK, Masaha R, Borkowi CB et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission: the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011: 8: e1001015.

30. Coovadia HM, Brown ER, Fowler MG et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012: 379: 221–228.

31. Shapiro RL, Kitch D, Ogwu A et al. HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana. AIDS 2013: 27: 1911–1920.

32. Jamieson DJ, Chasela CS, Hudgens MG et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012: 379: 2449–2458.

33. Nagot N, Kankasa C, Tumwine JK et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet 2015: 387: 566–573. PubMed PMID: 26603917. Epub 2015/11/26. Eng.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1 Modified Newcastle – Ottawa Quality Assessment Scale

Table S2 Excluded papers (Studies are based on published papers, which were screened based on the search criteria in Appendix 1. Some studies are additional outputs of larger studies that produced further papers and reports not considered in this study.) with reason for exclusion, after full text screening

Table S3 Included Studies: Descriptive information of studies providing information on breastfeeding and ART

Table S4 Assessment of studies HIV-free Survival in breastfed infants whose mothers were on ART based on the Modified Newcastle-Ottawa Scale

Table S5 Grade Evidence Profiles

**Corresponding Author** Lana Clara Chikhungu, Park Building, School of Languages and Area Studies, University of Portsmouth, King Henry 1 Street, Portsmouth, PO1 2DZ, UK. Tel.: +44 2392 846183; E-mail: lana.chikhungu@port.ac.uk